Source:http://linkedlifedata.com/resource/pubmed/id/15070682
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
8
|
pubmed:dateCreated |
2004-4-8
|
pubmed:abstractText |
Thrombophilic dysfibrinogen Tokyo V was identified in a 43-year-old man with recurrent thromboembolism. Based on analyses of the patient fibrinogen genes, the amino acid sequence of the aberrant fibrinogen peptide, and deglycosylation experiments, fibrinogen Tokyo V was shown to have an amino acid substitution of gamma Ala327Thr and possibly extra glycosylation at gamma Asn325 because the mutation confers the N-linked glycosylation consensus sequence Asn-X-Thr. The mutation resulted in impaired function and hypofibrinogenemia (hypodysfibrinogen). Polymerization of fibrin monomers derived from patient fibrinogen was severely impaired with a partial correction in the presence of calcium, resulting in very low clottability. Additionally, a large amount of soluble cross-linked fibrin was formed upon thrombin treatment in the presence of factor XIII and calcium. However, Tokyo V-derived fibrin was resistant to degradation by tissue plasminogen activator (tPA)-catalyzed plasmin digestion. The structure of Tokyo V fibrin appeared severely perturbed, since there are large pores inside the tangled fibrin networks and fiber ends at the boundaries. Taken together, these data suggest that Tokyo V fibrin clots are fragile, so that fibrinolysis-resistant insoluble fibrin and soluble fibrin polymers may be released to the circulation, partly accounting for the recurrent embolic episodes in the patient.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
0006-4971
|
pubmed:author |
pubmed-author:AoshimaMotonoriM,
pubmed-author:HamanoAkieiA,
pubmed-author:IshiwataAkiraA,
pubmed-author:ItohTakeyoshiT,
pubmed-author:KashiwakuraYujiY,
pubmed-author:KitamuraNoboruN,
pubmed-author:MadoiwaSeijiS,
pubmed-author:MatsudaMichioM,
pubmed-author:MimuroJunJ,
pubmed-author:NishinaritaSusumuS,
pubmed-author:NiwaKazukiK,
pubmed-author:OnoTomokoT,
pubmed-author:SakataYoichiY,
pubmed-author:SugoTerukoT,
pubmed-author:TakanoKatsuhiroK
|
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
103
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
3045-50
|
pubmed:dateRevised |
2009-11-19
|
pubmed:meshHeading |
pubmed-meshheading:15070682-Adult,
pubmed-meshheading:15070682-Amino Acid Substitution,
pubmed-meshheading:15070682-Calcium,
pubmed-meshheading:15070682-Fibrinogens, Abnormal,
pubmed-meshheading:15070682-Fibrinolysin,
pubmed-meshheading:15070682-Fibrinolysis,
pubmed-meshheading:15070682-Glycosylation,
pubmed-meshheading:15070682-Humans,
pubmed-meshheading:15070682-Male,
pubmed-meshheading:15070682-Microscopy, Electron, Scanning,
pubmed-meshheading:15070682-Recurrence,
pubmed-meshheading:15070682-Solubility,
pubmed-meshheading:15070682-Thromboembolism,
pubmed-meshheading:15070682-Thrombophilia,
pubmed-meshheading:15070682-Tissue Plasminogen Activator
|
pubmed:year |
2004
|
pubmed:articleTitle |
Thrombophilic dysfibrinogen Tokyo V with the amino acid substitution of gammaAla327Thr: formation of fragile but fibrinolysis-resistant fibrin clots and its relevance to arterial thromboembolism.
|
pubmed:affiliation |
Division of Cell and Molecular Medicine, Center for Molecular Medicine, Jichi Medical School, Tochigi-ken, Japan.
|
pubmed:publicationType |
Journal Article,
In Vitro,
Case Reports,
Research Support, Non-U.S. Gov't
|